Federal regulators say thousands of studies are missing required data, prompting a broad push for compliance with reporting laws.
By yourNEWS Media Newsroom
The U.S. Food and Drug Administration is calling on pharmaceutical companies and researchers to release missing clinical trial data, citing concerns that a significant number of studies subject to federal reporting requirements remain incomplete or undisclosed.
In a statement issued April 13, the agency said roughly 30 percent of clinical trials believed to fall under mandatory reporting rules have not submitted results to the government’s clinical trial database, a rate consistent with prior estimates.
To address the issue, the FDA said it sent more than 2,200 notices in late March to companies and researchers, reminding them of their legal obligation to report findings from completed studies.
“Far too often, companies are suppressing unfavorable clinical trial results and keeping them secret from patients and the scientific community,” said Marty Makary. “Those sponsoring clinical trials have an ethical obligation to make results public regardless of the data’s influence on the company’s share price.”
Makary added that incomplete reporting can hinder clinical decision-making. “Too many clinical trial sponsors and researchers are failing to report their results, leaving important information unavailable to clinicians and other researchers. If you are a doctor deciding whether or not to prescribe a medication to a patient, you deserve to have the best data about clinical studies on that medication.”
Federal law requires sponsors of many clinical trials to submit summary results within one year of completion, although certain early-stage studies, such as Phase 1 trials, are exempt from the requirement.
The FDA has the authority to initiate enforcement actions against noncompliant parties, including issuing notices of violation and levying fines that can reach up to $10,000. However, the agency indicated it is not currently pursuing penalties, opting instead to give companies additional time to comply voluntarily.
“The messages issued on March 30, 2026, represent an extra step the agency is taking to provide the relevant responsible parties with the opportunity to comply with federal law before the agency considers whether to take further regulatory action,” the agency said.
Only two formal notices of noncompliance have been issued so far in 2025, according to the FDA.
Tracy Beth Hoeg, acting director of the agency’s Center for Drug Evaluation and Research, said the outreach effort is intended to improve transparency and public access to medical data.
“I fully support this new initiative to increase the prompt publication—as required by law—of results information from interventional studies of the medical products we regulate,” Hoeg said. “We hope that the thousands of messages sent to sponsors and investigators reminding them to publicly report their findings will improve patient safety and keep researchers and the public better informed of benefits and risks of new and investigational products.”
The agency’s initiative reflects a broader effort to increase accountability in clinical research and ensure that healthcare providers and patients have access to comprehensive information when evaluating medical treatments.
Original article
Comments